Phase 1 Lymphoma Trial, Recruiting (NCT03557619)

Phase 1 Lymphoma Trial, Recruiting NCT03557619 Sponsor: AbbVie Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT03557619 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have non-Hodgkin's lymphoma (NHL) that has come back after treatment or has not responded to treatment.
People whose NHL has been confirmed by lab testing to be one of these specific types: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), T-cell prolymphocytic lymphoma (T-PLL), or Waldenström's macroglobulinemia (WM).
People who are generally able to carry out basic daily activities, based on a standard health scoring system called the ECOG scale (a score of 0, 1, or 2 out of 5).
People whose bone marrow, blood clotting, kidney, and liver are all functioning at levels described in the trial protocol (confirm with trial site).
Women who are not able to become pregnant, as defined by the trial protocol (confirm with trial site).

Who may not be able to join:

People who have a history of, or currently have, a significant heart or blood vessel condition.
People who have had a stem cell transplant within the last 100 days, or whose transplant was followed by graft-versus-host disease, or who are still receiving treatment to suppress the immune system after a transplant.
People whose lymphoma shows signs of having changed into a more aggressive form just before entering the trial.
People whose lymphoma has spread to the brain or spinal cord.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: 844-663-3742

Australian sites

Peter MacCallum Cancer Centre-East Melbourne /ID# 225247, East Melbourne, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03557619

Sponsor: AbbVie

Phase: Phase 1

Status: Recruiting

Condition: Lymphoma

Trial contact: 844-663-3742

More information: https://clinicaltrials.gov/study/NCT03557619

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have non-Hodgkin's lymphoma (NHL) that has come back after treatment or has not responded to treatment.
People whose NHL has been confirmed by lab testing to be one of these specific types: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), T-cell prolymphocytic lymphoma (T-PLL), or Waldenström's macroglobulinemia (WM).
People who are generally able to carry out basic daily activities, based on a standard health scoring system called the ECOG scale (a score of 0, 1, or 2 out of 5).
People whose bone marrow, blood clotting, kidney, and liver are all functioning at levels described in the trial protocol (confirm with trial site).
Women who are not able to become pregnant, as defined by the trial protocol (confirm with trial site).

Who may not be able to join:

People who have a history of, or currently have, a significant heart or blood vessel condition.
People who have had a stem cell transplant within the last 100 days, or whose transplant was followed by graft-versus-host disease, or who are still receiving treatment to suppress the immune system after a transplant.
People whose lymphoma shows signs of having changed into a more aggressive form just before entering the trial.
People whose lymphoma has spread to the brain or spinal cord.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

AbbVie

Registry

ClinicalTrials.gov

Start date

30 July 2019

Est. completion

21 March 2026

Where this trial is recruiting

🇦🇺 Australia 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Tmax of Venetoclax; Tmax of (ethinyl estradiol) EE/Levonorgestrel; Cmax of Venetoclax; Cmax of EE/Levonorgestrel; t1/2 of Venetoclax; t1/2 of EE/Levonorgestrel; AUCt of Venetoclax; AUCt of EE/Levonorgestrel; AUCinf of EE/Levonorgestrel

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov